Haukeland University Hospital
Bergen, Vestland, 5021, Norway
Location contact
Mathias S Æsøy, MD, PhD
CONTACT
Øyvind Ulvik, MD, PhD, Professor
CONTACT
NCT Number: NCT07741084
The primary aim of the study is to compare stone free rates following ureteroscopic (URS) lithotripsy for renal stones with Thulium Fiber Laser (TFL) using a sheathless approach (low power laser settings) or using a flexible and navigable ureteral access sheath (FANS) with either low power or high power laser settings. Secondary aims are to compare the results of sheathless- and FANS assisted URS lithotripsy in terms of operative time, laser time, intraoperative and postoperative complications. Following the primary comparison between sheathless and FANS groups, another aim is to compare the outcome of low power and high power URS lithotripsy in the FANS patients with respect to operative time, SFR, laser time, intraoperative and postoperative complications.
Patients ≥ 18 years with renal stones (8-25 mm) scheduled for URS lithotripsy at the Day Surgery Clinic at Haukeland University Hospital in Bergen, Akershus University Hospital and The Hospital of Vestfold - all renal stone centres in Norway, are eligible for inclusion in the study. After written consent and inclusion, patients are randomised to laser lithotripsy using one of three alternative ureteroscopic approaches: Group 1: Sheathless URS using low power TFL 4 -10 Watts, short pulse mode, Group 2: URS with FANS using low power TFL 4 - 10 Watts, short pulse mode or Group 3: URS with FANS using high power TFL 16 - 24 Watts, short pulse mode. The ureteroscopic procedures are performed in general anaesthesia using a standardised technique. All patients are followed up with a low dose CT scan 3 months post endoscopically to assess stone free status as well as a consultation at the outpatient clinic. Results and data for the three randomisation groups are compared according to the aims of the study.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Bergen, Vestland, 5021, Norway
Mathias S Æsøy, MD, PhD
CONTACT
Øyvind Ulvik, MD, PhD, Professor
CONTACT
BACKGROUND: Ureteroscopic laserlithotripsy (URS) is the preferred treatment modality for renal stones up to 20 - 25 mm. Continous development recent years with thinner flexible endoscopes, more efficient lasers and auxiliary eqiupment has expanded indications for URS. A few years ago, we performed a randomised clinical trial comparing URS lithotripsy using Holmium:YAG laser and Thulium Fiber Laser (TFL). The results of the study favoured TFL lithotripsy. However, there is no consensus regarding optimal laser settings using TFL. To address this issue, we recently performed another randomised clinical trial comparing URS lithotripsy using low and high TFL settings. In that study, low power laser settings resulted in significantly higher stone free rates and lower complication rates compared to high power lithotripsy. It should be noted that a sheathless approach was used in both groups. The sheathless approach used in this study has been criticised as the newly introduced flexible and navigable ureteral access sheath may improve stone free rates and reduce infectious complications.
However, to date, there are no clinical randomised trials comparing a sheathless approach and URS with FANS using different laser settings for TFL to determine what is optimal regarding the clinical outcomes.
AIMS OF THE STUDY: The primary aim of the study is to compare the stone free rates following URS lithotripsy for renal stones with low power TFL using a sheathless approach and URS with FANS (with low and high power settings). Secondary aims are to compare the results of sheathless- and FANS assisted URS lithotripsy in terms of operative time, laser time, intraoperative and postoperative complications. Following the primary comparison between sheathless and FANS groups, another aim is to compare the outcome of low power and high power URS lithotripsy in the FANS patients with respect to operative time, SFR, laser time, intraoperative and postoperative complications.
STUDY DESIGN: The study is planned as a multicenter prospective randomised clinical trial. All patients ≥ 18 years scheduled to URS lithotripsy for renal stones, 8-25 mm, at the day surgery unit at Haukeland University Hospital (HUH), Akershus University Hospital (AHUH) and The Hospital of Vestfold are invited to be enrolled in the study. After written informed consent, patients are randomised to laser lithotripsy using one of three alternative ureteroscopic approaches: Group 1: Sheathless URS using low power TFL 4 -10 Watts, short pulse mode, Group 2: URS with FANS using low power TFL 4 - 10 Watts, short pulse mode or Group 3: URS with FANS using high power TFL 16 - 24 Watts, short pulse mode.
In total, 225 patients will be included in the study, 75 from each of the three stone centres. Among the 75 patients recruited from each hospital, 25 will be randomised to each of the three randomisation groups.
LASER SETTINGS: The laser settings in the three study groups are standardised and need to be maintained throughout the procedure.
Standard start-up settings: Group 1 (sheathless, low power) 0.4J/10Hz (4W), Group 2 (FANS, low power) 0.6J/10Ηz (6W) and Group 3 (FANS, high power) 0.4J/40Hz (16W).
THE URS PROCEDURE: The URS procedure is performed in general anaesthesia and prophylactic antibiotics prior to surgery start will be administered according to the departments' guidelines, either according to urine culture or current local regime.
The procedure starts with flexible URS using the 7.5Fr single use MacroLux CoralView flexible ureteroscope with 6.7Fr wedged tip. Cystoscopy may be performed if considered necessary as well as semirigid ureteroscopy. A safety guide wire can be used at the surgeon's discretion but is routinely omitted during URS at the three hospitals. Balloon dilatation (4-5 mm) is performed on demand. However, multiple dilatations at different levels in the ureter should be avoided. Instead, a JJ-stent should be placed and the patient scheduled for a second procedure. If the patient is scheduled for a second procedure, they keep their allocated treatment group according to the first randomisation. Only the specific MacroLux flexible ureteroscope can be used for the endoscopic lithotripsy.
Room-tempered (23oC), gravitational irrigation fluid at 60 cm height is used throughout the procedure when performing a sheathless approach, and gravitational irrigation at ≥ 100 cm height when FANS are applied.
Patients are allocated to the randomisation group immediately once the entire ureter is inspected and confirmed stone free. Allocation to randomisation group is done by opening the sealed envelope revealing the result of the randomisation. FANS can be placed according to randomisation group only after performing initial endoscopy ensuring no stones are present in the ureter. The size of the FANS must be 9.5/11.5 Ch in the present study in the two FANS groups. However, if placement of a 9.5/11.5 Ch FANS fails an 8.5/10.5 Ch FANS can be attempted. Balloon dilatation can be performed as described above if deemed necessary. If placement of a FANS fails, the patient should still be included in the study but registered as failed access. However, per protocol analyses will be performed as it is of interest to explore the risk of failed placement of the sheaths. If a second procedure is planned, this should be performed according to the initial randomisation allocation group.
The amount of suction applied to the FANS can be adjusted according to the surgeons' discretion. A 150μm sized laser fibre must be used for stone disintegration for all patients across the randomisation groups. The stone is disintegrated using TFL with predefined settings as described below and according to the randomisation group. To make the procedures as similar as possible, the stone should be dusted/disintegrated to as small particles as possible rather than fragmented and retrieved. Only residual particles not suitable for further disintegration can be retrieved at the end of the procedure to render the patient stone free.
A JJ-stent can be placed after the procedure if deemed necessary, and if so, this is removed according to standard routine after 1-2 weeks in the outpatient clinic or by the patients themselves if on a string.
FOLLOW-UP: Follow-up with computed tomography (CT) is performed at 3 months post endoscopically for all patients to assess stone free status and exclude a ureteral stricture in addition to a clinical consultation.
ETHICAL CONSIDERATIONS AND APPROVALS: All patients eligible for inclusion in the study will receive oral and written information. Participation in the study is voluntarily, and the patient can choose to withdraw at any point during the study process. Inclusion in the study will only be done after the consent form is signed. The study is approved by The National Committees for Research Ethics in Norway (REK: 992079). In addition, approval by The Data Protection Authorities at Haukeland University Hospital (e-protocol: 6881)has been obtained.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sheathless URS using low laser power (4-6W), short pulse: 0.4 - 0.5J at 10 or 20Hz, or 0.6 - 0.8J at 10Hz. Standard start-up settings: 0.4J/10Hz (4W)
Sheathless URS using low laser power (4-6W), short pulse: 0.4 - 0.5J at 10 or 20Hz, or 0.6 - 0.8J at 10Hz. Standard start-up settings: 0.6J/10Hz (6W)
URS with FANS using high laser power (16-24W), short pulse: 0.4 - 0.5J at 40Hz, 0.6J at 30 - 40Hz, or 0.8J at 20 - 30Hz. Standard start-up settings: 0.4J/40Hz (16W)
Time frame: 3 months post endoscopically
Assessment of stone free status (or the presence of residual fragments) on low dose CT 3 months post endoscopically
Time frame: During surgery (approximately 1 hour), registered immediately after surgery
Surgical time in minutes, counted from start of the procedure with insertion of the endoscope until emptying the bladder in the end
Time frame: During surgery (approximately 1 hour), registered immediately after surgery
Duration of laser activation periods during laser lithotripsy in minutes
Time frame: During surgery (approximately 1 hour), registered immediately after surgery
Complications occurred during the endoscopic procedure (bleeding, perforation, avulsion, mucosal abrasion, blurred vision)
Time frame: After surgery until 3 months post endoscopically
Complications occurred after the endoscopic procedure (up to 3 months post endoscopically)
Time frame: During surgery (approximately 1 hour), registered immediately after surgery
Surgical time in minutes, counted from start of the procedure with insertion of the cystoscope until emptying the bladder in the end
Time frame: 3 months post endoscopically
Assessment of stone free status (or the presence of residual fragments) on low dose CT 3 months post endoscopically
Time frame: During surgery (approximately 1 hour), registered immediately after surgery
Duration of laser activation periods during laser lithotripsy in minutes
Time frame: During surgery (approximately 1 hour), registered immediately after surgery
Complications occurred during the endoscopic procedure (bleeding, perforation, avulsion, mucosal abrasion, blurred vision)
Time frame: After surgery until 3 months post endoscopically
Complications occurred after the endoscopic procedure (up to 3 months post endoscopically)
Contact information is provided by the study sponsor or research team.
Mathias S Æsøy, MD, PhD
CONTACT
Øyvind Ulvik, MD, PhD, Professor
CONTACT
Haukeland University Hospital
Other
FANS vs Sheathless URS Lithotripsy - a Prospective, Randomised Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07753096
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
View Trial DetailsNCT07155005
Calculi, Female Urogenital Diseases
View Trial DetailsNCT07393178
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
View Trial DetailsNCT07322471
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Shebin El-Kom, Menoufia, Egypt
View Trial Details